$RGPX
REGENEREX PHARMA, INC.

2024 Q3 Form 10-Q Financial Statement

#000147237524000074 Filed on August 07, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2 2023 Q2
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $160.2K
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $1.144K $831.00
YoY Change 37.67% -22.41%
% of Gross Profit
Operating Expenses $258.4K $254.3K $160.2K
YoY Change -90.73% 58.75% 826.66%
Operating Profit -$258.4K -$254.3K -$160.2K
YoY Change -90.73% 58.75% 826.66%
Interest Expense $266.2K $22.33K $18.51K
YoY Change 1244.16% 20.68% 19.26%
% of Operating Profit
Other Income/Expense, Net -$271.2K -$18.28K -$25.40K
YoY Change 1646.67% -28.03% 329.14%
Pretax Income
YoY Change
Income Tax
% Of Pretax Income
Net Earnings -$529.6K -$272.6K -$185.6K
YoY Change -81.1% 46.87% 699.75%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share
COMMON SHARES
Basic Shares Outstanding 278.3M shares 278.2M shares 277.1M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2024 Q3 2024 Q2 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $294.00 $67.75K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses $1.541K $2.357K $23.30K
Receivables
Other Receivables
Total Short-Term Assets $1.835K $2.357K $91.05K
YoY Change -90.51% -97.41% 2082.5%
LONG-TERM ASSETS
Property, Plant & Equipment $5.232K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $631.1K $726.7K $948.6K
YoY Change -30.9% -23.38% 14826.04%
TOTAL ASSETS
Total Short-Term Assets $1.835K $2.357K $91.05K
Total Long-Term Assets $631.1K $726.7K $948.6K
Total Assets $633.0K $729.1K $1.040M
YoY Change -32.13% -29.87% 9775.6%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $154.6K $160.7K $96.50K
YoY Change 72.1% 66.52% 67.86%
Accrued Expenses $126.3K $107.0K $76.97K
YoY Change 53.99% 38.97% -13.35%
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.851M $4.414M $801.7K
YoY Change 45.33% 450.5% 7.34%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $4.851M $4.414M $801.7K
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $5.390M $5.042M $2.124M
YoY Change 18.05% 137.45% 108.33%
SHAREHOLDERS EQUITY
Retained Earnings -$6.418M -$5.888M -$2.258M
YoY Change 26.86% 160.83% 15.31%
Common Stock $278.4K $278.3K $277.3K
YoY Change 0.19% 0.33% 0.08%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$4.757M -$4.313M -$1.084M
YoY Change
Total Liabilities & Shareholders Equity $633.0K $729.1K $1.040M
YoY Change -32.13% -29.87% 9775.6%

Cashflow Statement

Concept 2024 Q3 2024 Q2 2023 Q2
OPERATING ACTIVITIES
Net Income -$529.6K -$272.6K -$185.6K
YoY Change -81.1% 46.87% 699.75%
Depreciation, Depletion And Amortization $1.144K $831.00
YoY Change 37.67% -22.41%
Cash From Operating Activities -$55.33K -$121.2K
YoY Change -54.36% 245.72%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$3.629K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $54.96K $191.5K
YoY Change -71.3% 461.54%
NET CHANGE
Cash From Operating Activities -$55.33K -$121.2K
Cash From Investing Activities -$3.629K
Cash From Financing Activities $54.96K $191.5K
Net Change In Cash -$372.00 $66.62K
YoY Change -100.56% -6982.13%
FREE CASH FLOW
Cash From Operating Activities -$55.33K -$121.2K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
usd
CY2023Q2 RGPX Increase Decrease In Accrued Compensation
IncreaseDecreaseInAccruedCompensation
usd
CY2024Q2 us-gaap Payments To Acquire Furniture And Fixtures
PaymentsToAcquireFurnitureAndFixtures
usd
CY2024Q2 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
CY2024Q2 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
usd
CY2024Q2 us-gaap Income Taxes Paid
IncomeTaxesPaid
usd
CY2023Q2 us-gaap Income Taxes Paid
IncomeTaxesPaid
usd
CY2024Q2 us-gaap Interest Paid
InterestPaid
usd
CY2023Q2 us-gaap Interest Paid
InterestPaid
usd
CY2023Q2 RGPX Accrued Interest Converted Into Note Payable To Related Parties
AccruedInterestConvertedIntoNotePayableToRelatedParties
usd
CY2024Q2 RGPX Accrued Interest Converted Into Note Payable
AccruedInterestConvertedIntoNotePayable
usd
CY2024Q2 RGPX Operating Leases Rou Asset And Liabilities
OperatingLeasesRouAssetAndLiabilities
usd
CY2024Q2 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
5667 usd
CY2024Q1 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
6097 usd
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
254280 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
160174 usd
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
254280 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
160174 usd
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-254280 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-160174 usd
CY2024Q2 us-gaap Interest Expense
InterestExpense
22333 usd
CY2023Q2 us-gaap Interest Expense
InterestExpense
18506 usd
CY2024Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
4053 usd
CY2023Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-6895 usd
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-18280 usd
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-25401 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-272560 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-185575 usd
CY2024Q2 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.00
CY2023Q2 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.00
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
278226240 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
277156286 shares
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-272560 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-185575 usd
CY2024Q2 us-gaap Depreciation
Depreciation
1144 usd
CY2023Q2 us-gaap Depreciation
Depreciation
831 usd
CY2024Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
4053 usd
CY2023Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-6895 usd
CY2024Q2 us-gaap Share Based Compensation
ShareBasedCompensation
20997 usd
CY2023Q2 us-gaap Share Based Compensation
ShareBasedCompensation
34554 usd
CY2024Q2 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
29052 usd
CY2023Q2 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
380 usd
CY2024Q2 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
183 usd
CY2023Q2 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-23300 usd
CY2024Q2 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
63300 usd
CY2023Q2 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
93792 usd
CY2024Q2 RGPX Increase Decrease In Accrued Compensation
IncreaseDecreaseInAccruedCompensation
96885 usd
CY2024Q2 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
9720 usd
CY2023Q2 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-48814 usd
CY2024Q2 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-55332 usd
CY2023Q2 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-121237 usd
CY2023Q2 us-gaap Payments To Acquire Furniture And Fixtures
PaymentsToAcquireFurnitureAndFixtures
3629 usd
CY2023Q2 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3629 usd
CY2024Q2 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
1600 usd
CY2023Q2 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
1485 usd
CY2023Q2 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
190000 usd
CY2024Q2 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
54960 usd
CY2023Q2 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
191485 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-372 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
66619 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
372 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1135 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
67754 usd
CY2024Q2 RGPX Accrued Interest Converted Into Note Payable To Shareholder
AccruedInterestConvertedIntoNotePayableToShareholder
14264 usd
CY2023Q2 RGPX Accrued Interest Converted Into Note Payable To Shareholder
AccruedInterestConvertedIntoNotePayableToShareholder
20451 usd
CY2024Q2 RGPX Accrued Interest Converted Into Note Payable To Related Parties
AccruedInterestConvertedIntoNotePayableToRelatedParties
4866 usd
CY2023Q2 RGPX Accrued Interest Converted Into Note Payable
AccruedInterestConvertedIntoNotePayable
52545 usd
CY2023Q2 RGPX Operating Leases Rou Asset And Liabilities
OperatingLeasesRouAssetAndLiabilities
953535 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-1122947 usd
CY2023Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
190000 shares
CY2023Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
34554 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-185575 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-1083968 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-4061826 usd
CY2024Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
20997 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-272560 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-4313389 usd
CY2024Q2 us-gaap Nature Of Operations
NatureOfOperations
<p style="margin: 0px; font-size: 10pt"><b>NOTE 1 – NATURE OF OPERATIONS</b></p> <p style="margin: 0px; font-size: 10pt"> </p> <p style="margin: 0px; text-align: justify; font-size: 10pt">Regenerex Pharma, Inc., (the “Company” or “Regenerex”), was incorporated in the State of Nevada, United States of America, on November 18, 2005.</p> <p style="margin: 0px; font-size: 10pt"> </p> <p style="margin: 0px; text-align: justify; font-size: 10pt">On November 15, 2021, the Company entered into an Asset Purchase Agreement in which the Company purchased certain intellectual property in exchange for 150,000,000 shares of the Company’s common stock and up to $10,000,000 in contingent consideration to be paid at the rate of 15% of all gross revenues received from sales or investment money into the Company, payable on the 15<sup>th</sup> of the following month, for a period of 60 months.  On August 17, 2023, the Company entered into an Agreement to Purchase Technology Platforms in which the Company purchased certain intellectual property in exchange for an interest-free two million four hundred thousand dollars ($2,400,000) note payable that is due August 17, 2024.  The note payable is due within twelve (12) months of the date of the agreement.  If the Company has not raised a minimum of ten million dollars ($10,000,000) in sales within twelve (12) months, or a minimum of ten million dollars ($10,000,000) in investment, the seller will extend the payments for a further period of twelve (12) months for a 10% payment of the outstanding balance.</p> <p style="margin: 0px; text-align: justify; font-size: 10pt"> </p> <p style="margin: 0px; text-align: justify; font-size: 10pt">The Company received all rights and title to proprietary wound healing technologies platforms and formulas involving the application of wound care protocols to treat all wounds, such as diabetic ulcers, pressure ulcers, burns and surgical wounds.  These unique products strategically position the Company to enter the wound treatment market in the U.S.<span style="color: red"></span></p> <p style="margin: 0px; text-align: justify; font-size: 10pt"> </p> <p style="margin: 0px; text-align: justify; font-size: 10pt"><i>Risks and Uncertainties</i></p> <p style="margin: 0px; font-size: 10pt"> </p> <p style="margin: 0px; text-align: justify; font-size: 10pt">Our business and our forward-looking statements involve substantial known and unknown risks and uncertainties, including the risks and uncertainties inherent in our statements regarding the impacts of COVID-19, or other future pandemics on our business, results of operations, financial position, and cash flows.</p> <p style="margin: 0px; font-size: 10pt"> </p> <p style="margin: 0px; text-align: justify; font-size: 10pt">The Company has a lack of revenue history and has had a limited history of operations.  No revenue has historically been derived from the assets purchased.  Regenerex can give no assurance of success or profitability to the Company’s investors.</p> <p style="margin: 0px; text-align: justify; font-size: 10pt">The wound care healing space is well suited for Home Care service providers that are funded by the US Government. Strategic planning and development will be performed internally by the Company.<i></i></p> <p style="margin: 0px; text-align: justify; font-size: 10pt"> </p>
CY2024Q2 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2005-11-18
CY2021Q4 us-gaap Asset Acquisition Contingent Consideration Liability
AssetAcquisitionContingentConsiderationLiability
10000000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-4313389 usd
CY2024Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2734250 shares
CY2023Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1115000 shares
CY2024Q2 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P3Y
CY2024Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
714 usd
CY2023Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
715 usd
CY2024Q2 us-gaap Property Plant And Equipment Preproduction Design And Development Costs
PropertyPlantAndEquipmentPreproductionDesignAndDevelopmentCosts
<p style="margin: 0px; text-align: justify; font-size: 10pt"><i>Furniture and Computer Equipment</i></p> <p style="margin: 0px; font-size: 10pt"> </p> <p style="margin: 0px; text-align: justify; font-size: 10pt">Furniture and computer equipment are stated at cost, less accumulated depreciation.  Depreciation is computed using the straight-line method over the estimated useful life of three (3) to five (5) years.  Depreciation expense for the three months ended June 30, 2024 and 2023 was $430 and $116.  Significant betterments are capitalized while purchases under $500 are expensed as incurred.</p> <p style="margin: 0px; font-size: 10pt"> </p>
CY2024Q2 us-gaap Other Depreciation And Amortization
OtherDepreciationAndAmortization
430 usd
CY2023Q2 us-gaap Other Depreciation And Amortization
OtherDepreciationAndAmortization
116 usd
CY2024Q2 us-gaap Lessee Finance Lease Discount Rate
LesseeFinanceLeaseDiscountRate
0.10 pure
CY2024Q2 us-gaap Related Party Transaction Rate
RelatedPartyTransactionRate
0.10 pure
CY2024Q2 RGPX Related Party Advances
RelatedPartyAdvances
5290 usd
CY2024Q1 RGPX Related Party Advances
RelatedPartyAdvances
3690 usd
CY2024Q2 RGPX Notes Payable Related Parties
NotesPayableRelatedParties
168726 usd
CY2024Q1 RGPX Notes Payable To Related Parties Net Of Current Portion
NotesPayableToRelatedPartiesNetOfCurrentPortion
110500 usd
CY2024Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
3169 usd
CY2023Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
981 usd
CY2021Q4 us-gaap Business Combination Contingent Consideration Arrangements Description
BusinessCombinationContingentConsiderationArrangementsDescription
up to $10,000,000 in contingent consideration to be paid at the rate of 15% of all gross revenues received from sales or investment money into the Company, payable on the 15th of the following month, for a period of 60 months.
CY2021Q4 us-gaap Asset Acquisition Contingent Consideration Liability
AssetAcquisitionContingentConsiderationLiability
10000000 usd
CY2024Q2 us-gaap Lessee Operating Lease Description
LesseeOperatingLeaseDescription
On June 10, 2023, the Company entered into a plant facility lease agreement with a related party commencing June 9, 2023 which expires on June 30, 2028. Under this agreement, the monthly rental payments are $18,000 throughout the term of the lease excepting the month of June 2023 the rent is $7,920, The Company is working to have the premise certified by the FDA and will pay all related costs. Until the certification is complete, the monthly rent is reduced by forty (40%) percent to $10,800. Under this agreement, the Company is also leasing the equipment in the plant facility through five (5) annual rent payments of $10,000, which are due on the 15th day of each June from June 2023 to June 2027. The lease payment due June 15, 2024 is extended to September 15, 2024 with an extension fee of five hundred ($500) due August 5, 2024.
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
675000000 shares
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2734250 shares

Files In Submission

Name View Source Status
0001472375-24-000074-index-headers.html Edgar Link pending
0001472375-24-000074-index.html Edgar Link pending
0001472375-24-000074.txt Edgar Link pending
0001472375-24-000074-xbrl.zip Edgar Link pending
exhibit31-1.htm Edgar Link pending
exhibit31-2.htm Edgar Link pending
exhibit32-1.htm Edgar Link pending
exhibit32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
ixform10q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
ixform10q_htm.xml Edgar Link completed
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
regenerexlogo.gif Edgar Link pending
report.css Edgar Link pending
rgpx-20240630.xsd Edgar Link pending
Show.js Edgar Link pending
rgpx-20240630_cal.xml Edgar Link unprocessable
rgpx-20240630_def.xml Edgar Link unprocessable
rgpx-20240630_pre.xml Edgar Link unprocessable
rgpx-20240630_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable